FOLLICULAR LYMPHOMA

This study tested whether adding the drug ibrutinib to standard rituximab therapy helps people with untreated follicular lymphoma live longer without their cancer getting worse. About 445 patients aged 60 or older (or 60-69 with other health issues) took part. The main goal was t…

This study tested a treatment called tisagenlecleucel (a CAR-T cell therapy) in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells. The ma…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…

This study tested whether a combination of rituximab and lenalidomide works better than the standard rituximab plus chemotherapy for people with untreated follicular lymphoma. About 1,000 participants with advanced disease were enrolled. The goal was to see if the new combo impro…

This study tested a new treatment for children and young adults (ages 1-39) with B-cell leukemia or lymphoma that did not respond to standard therapy. The treatment involved taking a patient's own white blood cells, modifying them in a lab to target the CD22 protein on cancer cel…

This study tested a new radiation therapy schedule for people with B-cell lymphoma that has come back or not responded to treatment. Participants received radiation once a week for five weeks before their CAR T-cell therapy. The goal was to see if this schedule makes radiation ea…

This study tested a one-time treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had not responded to at least two prior treatments. The therapy works by reprogramming a patient's own immune cells to attack …

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…

This study looked back at 30 people with HIV who had already received CAR T-cell therapy for certain blood cancers. Researchers collected standard medical data to see what side effects occurred and how the immune system changed over time. The goal was to learn more about safety a…